Immune recovery and T cell subset analysis during effective treatment with maraviroc

Francesca Cossarini, Andrea Galli, Laura Galli, Alba Bigoloni, Stefania Salpietro, Concetta Vinci, Liviana Della torre, Nicola Gianotti, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna, Silvia Nozza

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Objectives: Patients treated with maraviroc frequently show high CD4+ T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery. Patients and methods: We studied T cell subsets from frozen peripheral blood mononuclear cells of patients treated with raltegravir, etravirine and either maraviroc (REM, n = 24) or darunavir/ritonavir (RED, n = 17). Results: The two groups showed a similar decrease in activated CD4+ and CD8+ T cells. A greater loss of naive CD4+ T cells and a reduction in cells expressing CXCR4 were observed in REM patients, while RED patients showed a greater loss of cells expressing CCR5. Conclusions: Our findings do not support a role for reduction in activated T cell subsets to explain the greater maraviroc-induced immune recovery. Reduction in CXCR4+CD4+ and higher expression of CCR5+CD4+ T cells might represent a potential protection from non-R5 tropic viral strain overgrowth.

Original languageEnglish
Article numberdks216
Pages (from-to)2474-2478
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Issue number10
StatePublished - Oct 2012
Externally publishedYes


  • CCR5
  • CXCR4
  • Darunavir
  • HIV
  • Immune activation
  • Maraviroc
  • Naive T cells


Dive into the research topics of 'Immune recovery and T cell subset analysis during effective treatment with maraviroc'. Together they form a unique fingerprint.

Cite this